Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

An error was introduced by the publisher during the typesetting process.

Table 3 ‘Summary of AEs over the full study period (PUNCH CD3 safety population; N = 267)’

Second column heading, which currently reads ‘Blinded Placebo (n = 870)’